{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:08:24Z","timestamp":1789196904810,"version":"build-2803163510"},"publisher-location":"Berlin, Heidelberg","reference-count":110,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_839","type":"book-chapter","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:23:01Z","timestamp":1789194181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PROTAC as a Potential Toolbox for the Discovery of New Targets and Drugs"],"prefix":"10.1007","author":[{"given":"Mengjun","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"key":"839_CR1","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1038\/s41467-023-39657-1","volume":"14","author":"M Bagka","year":"2023","unstructured":"Bagka M, Choi H, H\u00e9ritier M et al (2023) Targeted protein degradation reveals BET bromodomains as the cellular target of Hedgehog pathway inhibitor-1. Nat Commun 14:3893. https:\/\/doi.org\/10.1038\/s41467-023-39657-1","journal-title":"Nat Commun"},{"key":"839_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","volume":"36","author":"L Bai","year":"2019","unstructured":"Bai L, Zhou H, Xu R et al (2019) A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell 36:498\u2013511.e17. https:\/\/doi.org\/10.1016\/j.ccell.2019.10.002","journal-title":"Cancer Cell"},{"key":"839_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM (2022) PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21:181\u2013200. https:\/\/doi.org\/10.1038\/s41573-021-00371-6","journal-title":"Nat Rev Drug Discov"},{"key":"839_CR4","doi-asserted-by":"publisher","first-page":"15477","DOI":"10.1021\/acs.jmedchem.1c01532","volume":"64","author":"AG Bond","year":"2021","unstructured":"Bond AG, Craigon C, Chan K-H et al (2021) Development of BromoTag: a \u201cbump-and-hole\u201d\u2013PROTAC system to induce potent, rapid, and selective degradation of tagged target proteins. J Med Chem 64:15477\u201315502. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01532","journal-title":"J Med Chem"},{"key":"839_CR5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.chembiol.2018.11.006","volume":"26","author":"M Brand","year":"2019","unstructured":"Brand M, Jiang B, Bauer S et al (2019) Homolog-selective degradation as a strategy to probe the function of CDK6 in AML. Cell Chem Biol 26:300\u2013306.e9. https:\/\/doi.org\/10.1016\/j.chembiol.2018.11.006","journal-title":"Cell Chem Biol"},{"key":"839_CR6","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1021\/acschembio.5b00442","volume":"10","author":"DL Buckley","year":"2015","unstructured":"Buckley DL, Raina K, Darricarrere N et al (2015) HaloPROTACS: use of small molecule PROTACs to induce degradation of HaloTag fusion proteins. ACS Chem Biol 10:1831\u20131837. https:\/\/doi.org\/10.1021\/acschembio.5b00442","journal-title":"ACS Chem Biol"},{"key":"839_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","volume":"181","author":"GM Burslem","year":"2020","unstructured":"Burslem GM, Crews CM (2020) Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell 181:102\u2013114. https:\/\/doi.org\/10.1016\/j.cell.2019.11.031","journal-title":"Cell"},{"key":"839_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","volume":"19","author":"JH Bushweller","year":"2019","unstructured":"Bushweller JH (2019) Targeting transcription factors in cancer\u2014from undruggable to reality. Nat Rev Cancer 19:611\u2013624. https:\/\/doi.org\/10.1038\/s41568-019-0196-7","journal-title":"Nat Rev Cancer"},{"key":"839_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2021.672267","volume":"9","author":"C Cecchini","year":"2021","unstructured":"Cecchini C, Pannilunghi S, Tardy S, Scapozza L (2021) From conception to development: investigating PROTACs features for improved cell permeability and successful protein degradation. Front Chem 9:672267. https:\/\/doi.org\/10.3389\/fchem.2021.672267","journal-title":"Front Chem"},{"key":"839_CR10","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1541-7786.MCR-18-1242","volume":"17","author":"A-Y Chang","year":"2019","unstructured":"Chang A-Y, Hsu E, Patel J et al (2019) Evaluation of tumor cell\u2013tumor microenvironment component interactions as potential predictors of patient response to Napabucasin. Mol Cancer Res 17:1429\u20131434. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-1242","journal-title":"Mol Cancer Res"},{"key":"839_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jare.2023.10.014","volume":"63","author":"S Chen","year":"2024","unstructured":"Chen S, Bi K, Liang H et al (2024) PROTAC derivatization of natural products for target identification and drug discovery: design of evodiamine-based PROTACs as novel REXO4 degraders. J Adv Res 63:219\u2013230. https:\/\/doi.org\/10.1016\/j.jare.2023.10.014","journal-title":"J Adv Res"},{"key":"839_CR12","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1021\/acs.jmedchem.5c03213","volume":"69","author":"L Chen","year":"2026","unstructured":"Chen L, Bi T, Huang J et al (2026) Natural product\u2013inspired PROTACs for leukemia therapy: hederagenin-driven targeted degradation of SKP2. J Med Chem 69:4579\u20134601. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03213","journal-title":"J Med Chem"},{"key":"839_CR13","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1038\/cddis.2012.121","volume":"3","author":"G Cisbani","year":"2012","unstructured":"Cisbani G, Cicchetti F (2012) An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity. Cell Death Dis 3:e382. https:\/\/doi.org\/10.1038\/cddis.2012.121","journal-title":"Cell Death Dis"},{"key":"839_CR14","doi-asserted-by":"publisher","first-page":"17019","DOI":"10.1021\/jacs.8b08008","volume":"140","author":"PM Cromm","year":"2018","unstructured":"Cromm PM, Samarasinghe KTG, Hines J, Crews CM (2018) Addressing kinase-independent functions of FAK via PROTAC-mediated degradation. J Am Chem Soc 140:17019\u201317026. https:\/\/doi.org\/10.1021\/jacs.8b08008","journal-title":"J Am Chem Soc"},{"key":"839_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.immuni.2022.03.007","volume":"55","author":"L Cucolo","year":"2022","unstructured":"Cucolo L, Chen Q, Qiu J et al (2022) The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade. Immunity 55:671\u2013685.e10. https:\/\/doi.org\/10.1016\/j.immuni.2022.03.007","journal-title":"Immunity"},{"key":"839_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc.2017.36","volume":"17","author":"CV Dang","year":"2017","unstructured":"Dang CV, Reddy EP, Shokat KM, Soucek L (2017) Drugging the \u201cundruggable\u201d cancer targets. Nat Rev Cancer 17:502\u2013508. https:\/\/doi.org\/10.1038\/nrc.2017.36","journal-title":"Nat Rev Cancer"},{"key":"839_CR17","doi-asserted-by":"publisher","first-page":"15195","DOI":"10.1074\/jbc.RA118.003314","volume":"293","author":"D De Nardo","year":"2018","unstructured":"De Nardo D, Balka KR, Cardona Gloria Y et al (2018) Interleukin-1 receptor\u2013associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling. J Biol Chem 293:15195\u201315207. https:\/\/doi.org\/10.1074\/jbc.RA118.003314","journal-title":"J Biol Chem"},{"key":"839_CR18","doi-asserted-by":"publisher","first-page":"18024","DOI":"10.1021\/acs.jmedchem.5c00949","volume":"68","author":"B Ding","year":"2025","unstructured":"Ding B, Hu J, Shou B et al (2025) Phenotypic screening for targeted protein degradation: strategies, challenges, and emerging opportunities. J Med Chem 68:18024\u201318039. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00949","journal-title":"J Med Chem"},{"key":"839_CR19","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1039\/D5DD00300H","volume":"4","author":"N Dunlop","year":"2025","unstructured":"Dunlop N, Erazo F, Jalalypour F, Mercado R (2025) Predicting PROTAC-mediated ternary complexes with AlphaFold3 and Boltz-1. Digit Discov 4:3782\u20133809. https:\/\/doi.org\/10.1039\/D5DD00300H","journal-title":"Digit Discov"},{"key":"839_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nature21688","volume":"543","author":"MA Erb","year":"2017","unstructured":"Erb MA, Scott TG, Li BE et al (2017) Transcription control by the ENL YEATS domain in acute leukaemia. Nature 543:270\u2013274. https:\/\/doi.org\/10.1038\/nature21688","journal-title":"Nature"},{"key":"839_CR21","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202357677","volume":"24","author":"C Evrin","year":"2023","unstructured":"Evrin C, Alvarez V, Ainsworth J et al (2023) DONSON is required for CMG helicase assembly in the mammalian cell cycle. EMBO Rep 24:e57677. https:\/\/doi.org\/10.15252\/embr.202357677","journal-title":"EMBO Rep"},{"key":"839_CR22","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1021\/acscentsci.5c01594","volume":"11","author":"I Forrest","year":"2025","unstructured":"Forrest I, Conway LP, Jadhav AM et al (2025) Proteome-wide discovery of degradable proteins using Bifunctional molecules. ACS Cent Sci 11:2240\u20132256","journal-title":"ACS Cent Sci"},{"key":"839_CR23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nchembio.2329","volume":"13","author":"MS Gadd","year":"2017","unstructured":"Gadd MS, Testa A, Lucas X et al (2017) Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol 13:514\u2013521. https:\/\/doi.org\/10.1038\/nchembio.2329","journal-title":"Nat Chem Biol"},{"key":"839_CR24","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.1021\/acs.jmedchem.2c01864","volume":"66","author":"Y Gao","year":"2023","unstructured":"Gao Y, Jiang B, Kim H et al (2023) Catalytic degraders effectively address kinase site mutations in EML4-ALK oncogenic fusions. J Med Chem 66:5524\u20135535. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01864","journal-title":"J Med Chem"},{"key":"839_CR25","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1002\/anie.202012330","volume":"60","author":"A Ghidini","year":"2021","unstructured":"Ghidini A, Cl\u00e9ry A, Halloy F et al (2021) RNA-PROTACs: degraders of RNA-binding proteins. Angew Chem Int Ed 60:3163\u20133169. https:\/\/doi.org\/10.1002\/anie.202012330","journal-title":"Angew Chem Int Ed"},{"key":"839_CR26","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","volume":"30","author":"SM Gough","year":"2024","unstructured":"Gough SM, Flanagan JJ, Teh J et al (2024) Oral estrogen receptor PROTAC Vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models. Clin Cancer Res 30:3549\u20133563. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3465","journal-title":"Clin Cancer Res"},{"key":"839_CR27","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1021\/acsmedchemlett.1c00543","volume":"12","author":"CE Grigglestone","year":"2021","unstructured":"Grigglestone CE, Yeung K-S (2021) Degradation of protein kinases: ternary complex, cooperativity, and selectivity. ACS Med Chem Lett 12:1629\u20131632. https:\/\/doi.org\/10.1021\/acsmedchemlett.1c00543","journal-title":"ACS Med Chem Lett"},{"key":"839_CR28","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.chembiol.2020.12.001","volume":"28","author":"J Ha","year":"2021","unstructured":"Ha J, Park H, Park J, Park SB (2021) Recent advances in identifying protein targets in drug discovery. Cell Chem Biol 28:394\u2013423. https:\/\/doi.org\/10.1016\/j.chembiol.2020.12.001","journal-title":"Cell Chem Biol"},{"issue":"6","key":"839_CR29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","volume":"393","author":"EP Hamilton","year":"2025","unstructured":"Hamilton EP, Laurentiis MD, Jhaveri KL et al (2025) Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive\/human epidermal growth factor receptor 2 (HER2)\u2013negative advanced breast cancer: results of the global, randomized, phase 3 VERITAC-2 study. N Engl J Med 393(6):556\u2013568","journal-title":"N Engl J Med"},{"key":"839_CR30","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1021\/acs.jmedchem.0c01897","volume":"64","author":"M Hanafi","year":"2021","unstructured":"Hanafi M, Chen X, Neamati N (2021) Discovery of a Napabucasin PROTAC as an effective degrader of the E3 ligase ZFP91. J Med Chem 64:1626\u20131648. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01897","journal-title":"J Med Chem"},{"key":"839_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001819","volume":"9","author":"J Hou","year":"2021","unstructured":"Hou J, Wang Y, Shi L et al (2021) Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J Immunother Cancer 9:e001819. https:\/\/doi.org\/10.1136\/jitc-2020-001819","journal-title":"J Immunother Cancer"},{"key":"839_CR32","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"J Hughes","year":"2011","unstructured":"Hughes J, Rees S, Kalindjian S, Philpott K (2011) Principles of early drug discovery. Br J Pharmacol 162:1239\u20131249. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01127.x","journal-title":"Br J Pharmacol"},{"key":"839_CR33","doi-asserted-by":"publisher","first-page":"14132","DOI":"10.1073\/pnas.0907134106","volume":"106","author":"JM Hyman","year":"2009","unstructured":"Hyman JM, Firestone AJ, Heine VM et al (2009) Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci 106:14132\u201314137. https:\/\/doi.org\/10.1073\/pnas.0907134106","journal-title":"Proc Natl Acad Sci"},{"key":"839_CR34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1039\/D3SC04629J","volume":"15","author":"WT Jauslin","year":"2024","unstructured":"Jauslin WT, Schild M, Schaefer T et al (2024) A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3K\u03b1. Chem Sci 15:683\u2013691. https:\/\/doi.org\/10.1039\/D3SC04629J","journal-title":"Chem Sci"},{"key":"839_CR35","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41589-021-00765-y","volume":"17","author":"B Jiang","year":"2021","unstructured":"Jiang B, Gao Y, Che J et al (2021) Discovery and resistance mechanism of a selective CDK12 degrader. Nat Chem Biol 17:675\u2013683. https:\/\/doi.org\/10.1038\/s41589-021-00765-y","journal-title":"Nat Chem Biol"},{"key":"839_CR36","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.apsb.2025.01.021","volume":"15","author":"Y Jin","year":"2025","unstructured":"Jin Y, Qi X, Yu X et al (2025) Discovery of a potential hematologic malignancies therapy: selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function. Acta Pharm Sin B 15:1659\u20131679. https:\/\/doi.org\/10.1016\/j.apsb.2025.01.021","journal-title":"Acta Pharm Sin B"},{"key":"839_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR (2018) Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15:234\u2013248. https:\/\/doi.org\/10.1038\/nrclinonc.2018.8","journal-title":"Nat Rev Clin Oncol"},{"key":"839_CR38","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41589-022-01248-4","volume":"19","author":"A Kaneshige","year":"2023","unstructured":"Kaneshige A, Bai L, Wang M et al (2023) A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo. Nat Chem Biol 19:703\u2013711. https:\/\/doi.org\/10.1038\/s41589-022-01248-4","journal-title":"Nat Chem Biol"},{"key":"839_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4368","volume":"358","author":"S Klaeger","year":"2017","unstructured":"Klaeger S, Heinzlmeir S, Wilhelm M et al (2017) The target landscape of clinical kinase drugs. Science 358:eaan4368. https:\/\/doi.org\/10.1126\/science.aan4368","journal-title":"Science"},{"key":"839_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.str.2015.10.020","volume":"24","author":"JE Kung","year":"2016","unstructured":"Kung JE, Jura N (2016) Structural basis for the non-catalytic functions of protein kinases. Structure 24:7\u201324. https:\/\/doi.org\/10.1016\/j.str.2015.10.020","journal-title":"Structure"},{"key":"839_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai AC, Crews CM (2017) Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov 16:101\u2013114. https:\/\/doi.org\/10.1038\/nrd.2016.211","journal-title":"Nat Rev Drug Discov"},{"key":"839_CR42","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","volume":"146","author":"BY Lee","year":"2015","unstructured":"Lee BY, Timpson P, Horvath LG, Daly RJ (2015) FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther 146:132\u2013149. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.10.001","journal-title":"Pharmacol Ther"},{"key":"839_CR43","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1073\/pnas.1424171112","volume":"112","author":"Y Li","year":"2015","unstructured":"Li Y, Rogoff HA, Keates S et al (2015) Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci 112:1839\u20131844. https:\/\/doi.org\/10.1073\/pnas.1424171112","journal-title":"Proc Natl Acad Sci"},{"key":"839_CR44","doi-asserted-by":"publisher","unstructured":"Li Y, Meng Q, Wang P et al (2020) Identification of PDE6D as a potential target of sorafenib via PROTAC technology. https:\/\/doi.org\/10.1101\/2020.05.06.079947","DOI":"10.1101\/2020.05.06.079947"},{"key":"839_CR45","doi-asserted-by":"publisher","first-page":"11335","DOI":"10.1021\/acs.jmedchem.3c00824","volume":"66","author":"Y Li","year":"2023","unstructured":"Li Y, Zeng ZW, Chen D et al (2023) Facilitated drug repurposing with Artemisinin-derived PROTACs: unveiling PCLAF as a therapeutic target. J Med Chem 66:11335\u201311350. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00824","journal-title":"J Med Chem"},{"key":"839_CR46","doi-asserted-by":"publisher","first-page":"23926","DOI":"10.1021\/acsomega.5c01241","volume":"10","author":"Y Li","year":"2025","unstructured":"Li Y, Guo Y, Ma S et al (2025) Prodrug strategy for PROTACs: high efficiency and low toxicity. ACS Omega 10:23926\u201323942. https:\/\/doi.org\/10.1021\/acsomega.5c01241","journal-title":"ACS Omega"},{"key":"839_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108833","volume":"269","author":"T-T Liu","year":"2025","unstructured":"Liu T-T, Zeng K-W (2025) Recent advances in target identification technology of natural products. Pharmacol Ther 269:108833. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108833","journal-title":"Pharmacol Ther"},{"key":"839_CR48","doi-asserted-by":"publisher","first-page":"8902","DOI":"10.1021\/jacs.1c03852","volume":"143","author":"J Liu","year":"2021","unstructured":"Liu J, Chen H, Kaniskan H\u00dc et al (2021) TF-PROTACs enable targeted degradation of transcription factors. J Am Chem Soc 143:8902\u20138910. https:\/\/doi.org\/10.1021\/jacs.1c03852","journal-title":"J Am Chem Soc"},{"key":"839_CR49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.15212\/AMM-2024-0010","volume":"3","author":"Y Liu","year":"2024","unstructured":"Liu Y, Liang J, Zhu R et al (2024) Application of PROTACs in target identification and validation. Acta Mater Medica 3:72\u201387. https:\/\/doi.org\/10.15212\/AMM-2024-0010","journal-title":"Acta Mater Medica"},{"key":"839_CR50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.phytochem.2014.04.020","volume":"104","author":"J Lu","year":"2014","unstructured":"Lu J, Li G, Huang J et al (2014) Lathyrane-type diterpenoids from the seeds of Euphorbia lathyris. Phytochemistry 104:79\u201388. https:\/\/doi.org\/10.1016\/j.phytochem.2014.04.020","journal-title":"Phytochemistry"},{"key":"839_CR51","doi-asserted-by":"publisher","first-page":"8107","DOI":"10.1021\/jacs.5c14078","volume":"148","author":"P-C Lu","year":"2026","unstructured":"Lu P-C, Huang Y-A, Wali N et al (2026) PROTAC-mediated degradation of mHTT aggregates attenuates neurotoxicity in cellular and R6\/2 mouse models of Huntington\u2019s disease. J Am Chem Soc 148:8107\u20138121. https:\/\/doi.org\/10.1021\/jacs.5c14078","journal-title":"J Am Chem Soc"},{"key":"839_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-019-0270-9","volume":"14","author":"H Luo","year":"2019","unstructured":"Luo H, Vong CT, Chen H et al (2019) Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin Med 14:48. https:\/\/doi.org\/10.1186\/s13020-019-0270-9","journal-title":"Chin Med"},{"key":"839_CR53","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/nm.3951","volume":"21","author":"S-W Min","year":"2015","unstructured":"Min S-W, Chen X, Tracy TE et al (2015) Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21:1154\u20131162. https:\/\/doi.org\/10.1038\/nm.3951","journal-title":"Nat Med"},{"key":"839_CR54","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1002\/jcb.25152","volume":"116","author":"A Mondal","year":"2015","unstructured":"Mondal A, Chatterji U (2015) Artemisinin represses telomerase subunits and induces apoptosis in HPV-39 infected human cervical cancer cells. J Cell Biochem 116:1968\u20131981. https:\/\/doi.org\/10.1002\/jcb.25152","journal-title":"J Cell Biochem"},{"key":"839_CR55","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","volume":"14","author":"B Nabet","year":"2018","unstructured":"Nabet B, Roberts JM, Buckley DL et al (2018) The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol 14:431\u2013441. https:\/\/doi.org\/10.1038\/s41589-018-0021-8","journal-title":"Nat Chem Biol"},{"key":"839_CR56","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.canlet.2017.09.033","volume":"411","author":"HO Oladapo","year":"2017","unstructured":"Oladapo HO, Tarpley M, Sauer SJ et al (2017) Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells. Cancer Lett 411:136\u2013149. https:\/\/doi.org\/10.1016\/j.canlet.2017.09.033","journal-title":"Cancer Lett"},{"key":"839_CR57","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nchembio.2538","volume":"14","author":"CM Olson","year":"2018","unstructured":"Olson CM, Jiang B, Erb MA et al (2018) Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol 14:163\u2013170. https:\/\/doi.org\/10.1038\/nchembio.2538","journal-title":"Nat Chem Biol"},{"key":"839_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25168984","volume":"25","author":"NV Ortiz Zacar\u00edas","year":"2024","unstructured":"Ortiz Zacar\u00edas NV, R\u00f6th S, Broekhuis JD et al (2024) Inducing receptor degradation as a novel approach to target CC chemokine receptor 2 (CCR2). Int J Mol Sci 25:8984. https:\/\/doi.org\/10.3390\/ijms25168984","journal-title":"Int J Mol Sci"},{"key":"839_CR59","doi-asserted-by":"publisher","first-page":"8688","DOI":"10.1021\/acs.jmedchem.5c03330","volume":"69","author":"W Peng","year":"2026","unstructured":"Peng W, Pan X, Wang S et al (2026) New PROTAC designs for targeted protein degradation in 2021\u20132025: novel E3 ligases and pre-PROTACs. J Med Chem 69:8688\u20138718. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03330","journal-title":"J Med Chem"},{"issue":"6_suppl","key":"839_CR60","volume":"41","author":"DP Petrylak","year":"2023","unstructured":"Petrylak DP, Stewart TF, Gao X et al (2023) A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 41(6_suppl):TPS290","journal-title":"J Clin Oncol"},{"key":"839_CR62","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1039\/D5MD00095E","volume":"16","author":"S Pogash","year":"2025","unstructured":"Pogash S, Fletcher S (2025) Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradation. RSC Med Chem 16:2958\u20132973. https:\/\/doi.org\/10.1039\/D5MD00095E","journal-title":"RSC Med Chem"},{"key":"839_CR63","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1021\/jacs.4c17827","volume":"147","author":"B Racioppo","year":"2025","unstructured":"Racioppo B, Pechalrieu D, Abegg D et al (2025) Chemoproteomics-enabled De novo proteolysis targeting chimera discovery platform identifies a Metallothionein degrader to probe its role in cancer. J Am Chem Soc 147:7817\u20137828. https:\/\/doi.org\/10.1021\/jacs.4c17827","journal-title":"J Am Chem Soc"},{"key":"839_CR64","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1182\/blood-2021-147473","volume":"138","author":"DW Robbins","year":"2021","unstructured":"Robbins DW, Noviski M, Rountree R et al (2021) Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies. Blood 138:2251\u20132251. https:\/\/doi.org\/10.1182\/blood-2021-147473","journal-title":"Blood"},{"key":"839_CR65","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","volume":"67","author":"DW Robbins","year":"2024","unstructured":"Robbins DW, Noviski MA, Tan YS et al (2024) Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of Bruton\u2019s tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies. J Med Chem 67:2321\u20132336. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01007","journal-title":"J Med Chem"},{"key":"839_CR66","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejmech.2015.10.006","volume":"105","author":"D Rodr\u00edguez-Hern\u00e1ndez","year":"2015","unstructured":"Rodr\u00edguez-Hern\u00e1ndez D, Demuner AJ, Barbosa LCA et al (2015) Hederagenin as a triterpene template for the development of new antitumor compounds. Eur J Med Chem 105:57\u201362. https:\/\/doi.org\/10.1016\/j.ejmech.2015.10.006","journal-title":"Eur J Med Chem"},{"key":"839_CR67","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nrd3681","volume":"11","author":"JW Scannell","year":"2012","unstructured":"Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11:191\u2013200. https:\/\/doi.org\/10.1038\/nrd3681","journal-title":"Nat Rev Drug Discov"},{"key":"839_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202102555","volume":"8","author":"J Shao","year":"2021","unstructured":"Shao J, Yan Y, Ding D et al (2021) Destruction of DNA-binding proteins by programmable oligonucleotide PROTAC (O\u2019PROTAC): effective targeting of LEF1 and ERG. Adv Sci 8:2102555. https:\/\/doi.org\/10.1002\/advs.202102555","journal-title":"Adv Sci"},{"key":"839_CR69","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1021\/cr078350s","volume":"108","author":"Q-W Shi","year":"2008","unstructured":"Shi Q-W, Su X-H, Kiyota H (2008) Chemical and pharmacological research of the plants in genus Euphorbia. Chem Rev 108:4295\u20134327. https:\/\/doi.org\/10.1021\/cr078350s","journal-title":"Chem Rev"},{"key":"839_CR70","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.1021\/acs.jmedchem.1c02064","volume":"65","author":"Z Shi","year":"2022","unstructured":"Shi Z, Tian L, Qiang T et al (2022) From structure modification to drug launch: a systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy. J Med Chem 65:6390\u20136418. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c02064","journal-title":"J Med Chem"},{"key":"839_CR71","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.45457","volume":"8","author":"MC Silva","year":"2019","unstructured":"Silva MC, Ferguson FM, Cai Q et al (2019) Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. eLife 8:e45457. https:\/\/doi.org\/10.7554\/eLife.45457","journal-title":"eLife"},{"key":"839_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08027-7","volume":"10","author":"BE Smith","year":"2019","unstructured":"Smith BE, Wang SL, Jaime-Figueroa S et al (2019) Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat Commun 10:131. https:\/\/doi.org\/10.1038\/s41467-018-08027-7","journal-title":"Nat Commun"},{"issue":"4","key":"839_CR73","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","volume":"24","author":"LB Snyder","year":"2025","unstructured":"Snyder LB, Neklesa TK, Willard RR et al (2025) Preclinical evaluation of Bavdegalutamide (ARV-110), a novel PROteolysis TArgeting chimera androgen receptor degrader. Mol Cancer Ther 24(4):511\u2013522","journal-title":"Mol Cancer Ther"},{"key":"839_CR74","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2217\/fon-2018-0903","volume":"15","author":"MB Sonbol","year":"2019","unstructured":"Sonbol MB, Ahn DH, Goldstein D et al (2019) Canstem111P trial: a phase III study of Napabucasin plus nab-paclitaxel with gemcitabine. Fut Oncol 15:1295\u20131302. https:\/\/doi.org\/10.2217\/fon-2018-0903","journal-title":"Fut Oncol"},{"key":"839_CR75","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fnins.2017.00064","volume":"11","author":"E Stroo","year":"2017","unstructured":"Stroo E, Koopman M, Nollen EAA, Mata-Cabana A (2017) Cellular regulation of amyloid formation in aging and disease. Front Neurosci 11:64. https:\/\/doi.org\/10.3389\/fnins.2017.00064","journal-title":"Front Neurosci"},{"key":"839_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0101-6","volume":"4","author":"X Sun","year":"2019","unstructured":"Sun X, Gao H, Yang Y et al (2019) PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther 4:64. https:\/\/doi.org\/10.1038\/s41392-019-0101-6","journal-title":"Signal Transduct Target Ther"},{"key":"839_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.113164","volume":"262","author":"Q Sun","year":"2020","unstructured":"Sun Q, Xie L, Song J, Li X (2020) Evodiamine: a review of its pharmacology, toxicity, pharmacokinetics and preparation researches. J Ethnopharmacol 262:113164. https:\/\/doi.org\/10.1016\/j.jep.2020.113164","journal-title":"J Ethnopharmacol"},{"issue":"47","key":"839_CR78","volume":"11","author":"Y Sun","year":"2025","unstructured":"Sun Y, Liu S, Chen L et al (2025) AI-driven discovery of dual antiaging and anti-AD therapeutics via PROTAC target deconvolution of a super-enhancer\u2013regulated axis. Sci Adv 11(47):eadz9283","journal-title":"Sci Adv"},{"key":"839_CR79","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrd3480","volume":"10","author":"DC Swinney","year":"2011","unstructured":"Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10:507\u2013519. https:\/\/doi.org\/10.1038\/nrd3480","journal-title":"Nat Rev Drug Discov"},{"key":"839_CR80","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216959","volume":"15","author":"J Taubenschmid-Stowers","year":"2023","unstructured":"Taubenschmid-Stowers J, Orthofer M, Laemmerer A et al (2023) A whole-genome scan for Artemisinin cytotoxicity reveals a novel therapy for human brain tumors. EMBO Mol Med 15:e16959. https:\/\/doi.org\/10.15252\/emmm.202216959","journal-title":"EMBO Mol Med"},{"key":"839_CR81","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1021\/acschembio.9b00505","volume":"14","author":"H Tovell","year":"2019","unstructured":"Tovell H, Testa A, Zhou H et al (2019) Design and characterization of SGK3-PROTAC1, an isoform specific SGK3 kinase PROTAC degrader. ACS Chem Biol 14:2024\u20132034. https:\/\/doi.org\/10.1021\/acschembio.9b00505","journal-title":"ACS Chem Biol"},{"key":"839_CR82","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.27159","volume":"2","author":"Z Wang","year":"2013","unstructured":"Wang Z, Bunting KD (2013) STAT5 in hematopoietic stem cell biology and transplantation. JAK-STAT 2:e27159. https:\/\/doi.org\/10.4161\/jkst.27159","journal-title":"JAK-STAT"},{"key":"839_CR83","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41589-021-00742-5","volume":"17","author":"L Wang","year":"2021","unstructured":"Wang L, Shao X, Zhong T et al (2021) Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Nat Chem Biol 17:567\u2013575. https:\/\/doi.org\/10.1038\/s41589-021-00742-5","journal-title":"Nat Chem Biol"},{"key":"839_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02483-2","volume":"41","author":"K Wang","year":"2022","unstructured":"Wang K, Dai X, Yu A et al (2022a) Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression. J Exp Clin Cancer Res 41:289. https:\/\/doi.org\/10.1186\/s13046-022-02483-2","journal-title":"J Exp Clin Cancer Res"},{"key":"839_CR85","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1021\/acs.jmedchem.1c01978","volume":"65","author":"Z Wang","year":"2022","unstructured":"Wang Z, Huang W, Zhou K et al (2022b) Targeting the non-catalytic functions: a new paradigm for kinase drug discovery? J Med Chem 65:1735\u20131748. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01978","journal-title":"J Med Chem"},{"key":"839_CR86","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1182\/blood-2024-202909","volume":"144","author":"H Wang","year":"2024","unstructured":"Wang H, Zhou Q, Li L et al (2024) Bgb-16673, a selective BTK degrader, exhibits deeper inhibition of cancer cell signaling pathways and better efficacy in MCL models. Blood 144:5833\u20135833. https:\/\/doi.org\/10.1182\/blood-2024-202909","journal-title":"Blood"},{"key":"839_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202417278","volume":"12","author":"J Wang","year":"2025","unstructured":"Wang J, He P, Liu C et al (2025) Discovery of natural compound \u03b1-Hederin via large-scale screening as a targeted JAK\/STAT3 inhibitor for ovarian cancer therapy. Adv Sci 12:e17278. https:\/\/doi.org\/10.1002\/advs.202417278","journal-title":"Adv Sci"},{"key":"839_CR88","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u20137109. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1443","journal-title":"Cancer Res"},{"key":"839_CR89","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm SM, Adnane L, Newell P et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129\u20133140. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0013","journal-title":"Mol Cancer Ther"},{"key":"839_CR90","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1039\/C6NP00001K","volume":"33","author":"MH Wright","year":"2016","unstructured":"Wright MH, Sieber SA (2016) Chemical proteomics approaches for identifying the cellular targets of natural products. Nat Prod Rep 33:681\u2013708. https:\/\/doi.org\/10.1039\/C6NP00001K","journal-title":"Nat Prod Rep"},{"key":"839_CR91","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1016\/j.apsb.2022.07.007","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yang Y, Wang W et al (2022) PROTAC technology as a novel tool to identify the target of lathyrane diterpenoids. Acta Pharm Sin B 12:4262\u20134265. https:\/\/doi.org\/10.1016\/j.apsb.2022.07.007","journal-title":"Acta Pharm Sin B"},{"key":"839_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101176","volume":"78","author":"D Wu","year":"2025","unstructured":"Wu D, Sun Q, Tang H et al (2025) Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies. Drug Resist Updat 78:101176. https:\/\/doi.org\/10.1016\/j.drup.2024.101176","journal-title":"Drug Resist Updat"},{"key":"839_CR93","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1038\/s41467-023-39904-5","volume":"14","author":"RP Wurz","year":"2023","unstructured":"Wurz RP, Rui H, Dellamaggiore K et al (2023) Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation. Nat Commun 14:4177. https:\/\/doi.org\/10.1038\/s41467-023-39904-5","journal-title":"Nat Commun"},{"key":"839_CR94","doi-asserted-by":"publisher","first-page":"9866","DOI":"10.1039\/D0CC03243C","volume":"56","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Wang J, Zhao LY et al (2020) Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs. Chem Commun 56:9866\u20139869. https:\/\/doi.org\/10.1039\/D0CC03243C","journal-title":"Chem Commun"},{"key":"839_CR95","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.chembiol.2023.07.010","volume":"30","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Hale S, Awasthee N et al (2023) HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation. Cell Chem Biol 30:1421\u20131435.e12. https:\/\/doi.org\/10.1016\/j.chembiol.2023.07.010","journal-title":"Cell Chem Biol"},{"key":"839_CR96","doi-asserted-by":"publisher","first-page":"12784","DOI":"10.1021\/acs.jmedchem.4c00761","volume":"67","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Awasthee N, Liu Y et al (2024) Discovery of a highly potent and selective HDAC8 degrader: advancing the functional understanding and therapeutic potential of HDAC8. J Med Chem 67:12784\u201312806. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00761","journal-title":"J Med Chem"},{"key":"839_CR97","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1021\/acs.jmedchem.4c02032","volume":"68","author":"W Xie","year":"2025","unstructured":"Xie W, Li H, Yu T et al (2025) Design and synthesis of Hederagenin derivatives for the treatment of sepsis by targeting TAK1 and regulating the TAK1-NF-\u03baB\/MAPK signaling. J Med Chem 68:2694\u20132719. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02032","journal-title":"J Med Chem"},{"key":"839_CR98","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-11-0950","volume":"18","author":"Y Xu","year":"2012","unstructured":"Xu Y, Chenna V, Hu C et al (2012) Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 18:1291\u20131302. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0950","journal-title":"Clin Cancer Res"},{"key":"839_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116725","volume":"276","author":"S Yan","year":"2024","unstructured":"Yan S, Zhang G, Luo W et al (2024) PROTAC technology: from drug development to probe technology for target deconvolution. Eur J Med Chem 276:116725. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116725","journal-title":"Eur J Med Chem"},{"key":"839_CR100","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nrm2346","volume":"9","author":"X-J Yang","year":"2008","unstructured":"Yang X-J, Seto E (2008) The Rpd3\/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 9:206\u2013218. https:\/\/doi.org\/10.1038\/nrm2346","journal-title":"Nat Rev Mol Cell Biol"},{"key":"839_CR101","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y, Li S, Wang Y et al (2022) Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther 7:329. https:\/\/doi.org\/10.1038\/s41392-022-01168-8","journal-title":"Signal Transduct Target Ther"},{"key":"839_CR102","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3390\/molecules18021826","volume":"18","author":"H Yu","year":"2013","unstructured":"Yu H, Jin H, Gong W et al (2013) Pharmacological actions of multi-target-directed Evodiamine. Molecules 18:1826\u20131843. https:\/\/doi.org\/10.3390\/molecules18021826","journal-title":"Molecules"},{"key":"839_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55006-2","volume":"15","author":"X Yu","year":"2024","unstructured":"Yu X, Lu D, Qi X et al (2024) Development of a RIPK1 degrader to enhance antitumor immunity. Nat Commun 15:10683. https:\/\/doi.org\/10.1038\/s41467-024-55006-2","journal-title":"Nat Commun"},{"key":"839_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.115000","volume":"247","author":"Z Zeng","year":"2023","unstructured":"Zeng Z, Chen D, Chen L et al (2023) A comprehensive overview of Artemisinin and its derivatives as anticancer agents. Eur J Med Chem 247:115000. https:\/\/doi.org\/10.1016\/j.ejmech.2022.115000","journal-title":"Eur J Med Chem"},{"key":"839_CR105","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M (2017) WNT signaling in cancer. Oncogene 36:1461\u20131473. https:\/\/doi.org\/10.1038\/onc.2016.304","journal-title":"Oncogene"},{"key":"839_CR106","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1021\/acs.jnatprod.8b00600","volume":"82","author":"C-Y Zhang","year":"2019","unstructured":"Zhang C-Y, Wu Y-L, Zhang P et al (2019) Anti-inflammatory Lathyrane Diterpenoids from Euphorbia lathyris. J Nat Prod 82:756\u2013764. https:\/\/doi.org\/10.1021\/acs.jnatprod.8b00600","journal-title":"J Nat Prod"},{"key":"839_CR107","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tips.2015.10.001","volume":"37","author":"C Zhao","year":"2016","unstructured":"Zhao C, Li H, Lin H-J et al (2016) Feedback activation of STAT3 as a cancer drug-resistance mechanism. Trends Pharmacol Sci 37:47\u201361. https:\/\/doi.org\/10.1016\/j.tips.2015.10.001","journal-title":"Trends Pharmacol Sci"},{"key":"839_CR108","doi-asserted-by":"publisher","first-page":"18022","DOI":"10.1021\/acs.jmedchem.4c01305","volume":"67","author":"X Zheng","year":"2024","unstructured":"Zheng X, Ji N, Campbell V et al (2024) Discovery of KT-474\u2500a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases. J Med Chem 67:18022\u201318037. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01305","journal-title":"J Med Chem"},{"key":"839_CR109","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1021\/acs.jmedchem.3c01719","volume":"67","author":"W Zhu","year":"2024","unstructured":"Zhu W, Zhang W, Chen J et al (2024a) Discovery of effective dual PROTAC degraders for neurodegenerative disease-associated aggregates. J Med Chem 67:3448\u20133466. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01719","journal-title":"J Med Chem"},{"key":"839_CR110","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1021\/acs.jmedchem.4c00107","volume":"67","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Ye X, Wu Y et al (2024b) Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting C797S mutation. J Med Chem 67:7283\u20137300. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00107","journal-title":"J Med Chem"},{"key":"839_CR111","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/med.22113","volume":"45","author":"B Zhu","year":"2025","unstructured":"Zhu B, Wu Z, Shou Y et al (2025) Harnessing the power of natural products for targeted protein degradation. Med Res Rev 45:1466\u20131514. https:\/\/doi.org\/10.1002\/med.22113","journal-title":"Med Res Rev"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:23:04Z","timestamp":1789194184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":110,"URL":"https:\/\/doi.org\/10.1007\/164_2026_839","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"13 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}